Related Experiment Videos
Rifampin in the treatment of serious staphylococcal infections
Abstract:
Eight patients with serious staphylococcal infections such as endocarditis, meningitis, epidural abscess, shunt and graft infections were treated with nafcillin, cephalothin or vancomycin in combination with rifampin. In vitro antibiotic sensitivities demonstrated that the Staphylococcus aureus and Staphylococcus epidermidis were highly sensitive to rifampin with minimum inhibitory and bactericidal levels of .0078-.25 micrograms/ml. In all patients reviewed and reported, when serum bactericidal levels were measured before and after the addition of rifampin, there was a positive correlation between microbiological and clinical outcome. Thus, in selected patients with life-threatening infections caused by S. aureus and S. epidermidis rifampin should be considered an adjunctive therapy.
Insights
Rifampin, combined with other antibiotics, shows promise for treating severe staphylococcal infections. This adjunctive therapy demonstrated a positive correlation between microbiological and clinical outcomes in patients with serious Staphylococcus aureus and Staphylococcus epidermidis infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Serious staphylococcal infections, including endocarditis, meningitis, and abscesses, pose significant clinical challenges.
- Standard antibiotic regimens may not always achieve optimal outcomes for severe Staphylococcus aureus and Staphylococcus epidermidis infections.
Observation:
- Eight patients with severe staphylococcal infections were treated with nafcillin, cephalothin, or vancomycin in combination with rifampin.
- In vitro studies revealed high sensitivity of Staphylococcus aureus and Staphylococcus epidermidis to rifampin, with low minimum inhibitory and bactericidal levels (0.0078-0.25 µg/ml).
Findings:
- A positive correlation was observed between serum bactericidal levels and both microbiological and clinical outcomes after the addition of rifampin.
- The combination therapy demonstrated efficacy in patients with life-threatening infections caused by S. aureus and S. epidermidis.
Implications:
- Rifampin should be considered as an adjunctive therapy for selected patients with severe staphylococcal infections.
- This finding supports the expanded use of rifampin in managing challenging Gram-positive bacterial infections.
- Further research into optimal dosing and duration of rifampin combination therapy is warranted.